Integrative Chemo-immunological Strategies in Cancer Treatment: Natural Compounds, Nanocarriers, and Targeted Therapeutic Approaches

Cancer remains a major global health burden, driven by tumor heterogeneity, therapeutic resistance, and the limited efficacy of conventional treatment modalities. Chemical and immunological approaches have emerged as complementary strategies with the potential to enhance therapeutic precision and clinical outcomes. Chemical agents, including natural compounds, small-molecule synthetic inhibitors, and targeted inhibitors, exert anticancer activity by inducing apoptosis, inhibiting oncogenic signalling, modulating oxidative stress, and regulating epigenetic pathways. In parallel, immunotherapeutic modalities such as monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies activate host immunity to generate durable antitumor responses and long-term immune memory. The integration of chemical and immunological strategies produces synergistic effects that strengthen tumor control. Phytochemicals modulate immune checkpoints and reprogram the tumor microenvironment (TME), while nanocarrier-based platforms enable co-delivery of chemotherapeutics and immunomodulators, improving bioavailability and reducing systemic toxicity. Targeted kinase inhibitors increase tumor antigenicity and sensitize malignant cells to immune checkpoint blockade, providing a mechanistic foundation for rational combination regimens. These integrated approaches collectively remodel the TME, bypass resistance mechanisms, and elicit robust antitumor responses. Despite these advances, significant challenges persist, including immune-related toxicities, TME-mediated resistance, high treatment costs, and interpatient variability. Emerging technologies such as AI-driven drug discovery, multi-omic and spatial transcriptomic profiling, and personalized immunotherapy platforms enable high-resolution mapping of tumor heterogeneity, immune signatures, and drug sensitivities. These innovations support the development of patient-specific therapeutic combinations that optimize immune activation, enhance drug delivery, and improve clinical efficacy. The convergence of chemical, immunological, and computational strategies represents a critical direction for next-generation oncology, offering the potential for more effective, safer, and high-precision cancer therapies.